Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme

Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme

Preexisting humoral immunity to recombinant adeno-associated virus (AAV) vectors restricts the treatable patient population and efficacy of human gene therapies. Approaches to clear neutralizing antibodies (NAbs), such as plasmapheresis and immunosuppression, are either ineffective or cause undesira...

Full description

Bibliographic Details
Main Authors: Zachary C. Elmore, Daniel K. Oh, Katherine E. Simon, Marco M. Fanous, Aravind Asokan
Format: Article
Language:English
Published: American Society for Clinical investigation 2020-10-01
Series:JCI Insight
Subjects:
Immunology
Therapeutics
Online Access:https://doi.org/10.1172/jci.insight.139881

Similar Items

Similar Items